AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+11.4%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$254M
AUM Growth
+$254M
(-2.4%)
Cap. Flow
-$24.8M
Cap. Flow
% of AUM
-9.74%
Top 10 Holdings %
Top 10 Hldgs %
51.68%
Holding
90
New
19
Increased
14
Reduced
15
Closed
19
Top Buys
| 1 |
Teva Pharmaceuticals
TEVA
|
$12M |
| 2 |
Biogen
BIIB
|
$11.4M |
| 3 |
Prothena Corp
PRTA
|
$6.83M |
| 4 |
Establishment Labs
ESTA
|
$6.75M |
| 5 |
Kura Oncology
KURA
|
$5.85M |
Top Sells
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$25.2M |
| 2 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$16.1M |
| 3 |
Merck
MRK
|
$12.8M |
| 4 |
BLU
BELLUS Health Inc.
BLU
|
$6.35M |
| 5 |
Ventyx Biosciences
VTYX
|
$5.23M |
Sector Composition
| 1 | Healthcare | 94.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Celldex Therapeutics
CLDX
$1.57B
| $2.95M | 1.03% |
87,031
+37,031
| +74% | +$1.26M |
|
27
FibroGen
FGEN
$48.4M
| $2.65M | 0.93% |
+983,300
| New | +$2.65M |
|
28
Xenon Pharmaceuticals
XENE
$2.99B
| $2.32M | 0.81% |
60,376
-29,624
| -33% | -$1.14M |
|
|
THRX
29
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $2.24M | 0.78% |
240,244
+142,023
| +145% | +$1.33M |
|
30
Spyre Therapeutics
SYRE
$1.02B
| $2.21M | 0.77% |
+4,900,000
| New | +$2.21M |
|
|
VINC
31
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $1.94M | 0.68% |
1,492,771
| – | – |
|
|
LIAN
32
DELISTED
LianBio American Depositary Shares
LIAN
| $1.83M | 0.64% |
800,676
+150,676
| +23% | +$344K |
|
33
Cabaletta Bio
CABA
$144M
| $1.61M | 0.56% |
+125,000
| New | +$1.61M |
|
34
KalVista Pharmaceuticals
KALV
$713M
| $1.6M | 0.56% |
178,292
-30,000
| -14% | -$270K |
|
35
ADC Therapeutics
ADCT
$370M
| $1.29M | 0.45% |
600,000
| – | – |
|
|
WHWK
36
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.3M
| $1.28M | 0.45% |
+187,675
| New | +$1.28M |
|
37
Aldeyra Therapeutics
ALDX
$350M
| $1.26M | 0.44% |
+150,000
| New | +$1.26M |
|
|
ALPN
38
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $1.22M | 0.43% |
118,891
-129,000
| -52% | -$1.33M |
|
39
NewAmsterdam Pharma
NAMS
$2.8B
| $1.19M | 0.42% |
+100,000
| New | +$1.19M |
|
40
InflaRx
IFRX
$117M
| $1.07M | 0.37% |
+240,200
| New | +$1.07M |
|
41
Mineralys Therapeutics
MLYS
$1.94B
| $1.07M | 0.37% |
62,500
| – | – |
|
42
Nurix Therapeutics
NRIX
$723M
| $999K | 0.35% |
100,000
-50,000
| -33% | -$500K |
|
43
BioAtla
BCAB
$28.7M
| $975K | 0.34% |
325,000
| – | – |
|
44
Apellis Pharmaceuticals
APLS
$3.51B
| $911K | 0.32% |
10,000
-25,000
| -71% | -$2.28M |
|
45
Axsome Therapeutics
AXSM
$6.09B
| $898K | 0.31% |
+12,500
| New | +$898K |
|
46
Milestone Pharmaceuticals
MIST
$151M
| $855K | 0.3% |
300,068
+100,686
| +50% | +$287K |
|
47
Mirum Pharmaceuticals
MIRM
$3.75B
| $776K | 0.27% |
30,000
-65,000
| -68% | -$1.68M |
|
48
Puma Biotechnology
PBYI
$258M
| $714K | 0.25% |
202,349
+25,000
| +14% | +$88.3K |
|
49
Vaxcyte
PCVX
$4.17B
| $695K | 0.24% |
13,923
-48,300
| -78% | -$2.41M |
|
50
Jasper Therapeutics
JSPR
$44.2M
| $653K | 0.23% |
476,948
| – | – |
|